ALK and neoplasm: In accordance with the clinical recommendations of the Russian Association of Oncologists (AOR), taking into account the molecular profile of the tumor (ALK mutation), targeted therapy with the drug Alecensa (alectinib, F. Hoffmann-La Roche Ltd., Basel, Switzerland) was started.